Scarica l'app Stockscreener
3.94
1.01%
-0.04
Precedente Chiudi:
$3.98
Aprire:
$4.06
Volume 24 ore:
163.59K
Relative Volume:
0.79
Capitalizzazione di mercato:
$81.96M
Reddito:
-
Utile/perdita netta:
$-117.17M
Rapporto P/E:
-0.3397
EPS:
-11.6
Flusso di cassa netto:
$-91.71M
1 W Prestazione:
-11.66%
1M Prestazione:
-10.45%
6M Prestazione:
-45.20%
1 anno Prestazione:
-80.00%
Intervallo 1D:
$3.92
$4.075
Intervallo di 1 settimana:
$3.92
$4.63
Portata 52W:
$3.845
$22.40
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Nome
Adverum Biotechnologies Inc
Settore
Industria
Telefono
(650) 649-1004
Indirizzo
100 CARDINAL WAY, REDWOOD CITY, CA
Confronta ADVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
3.94 | 81.96M | 0 | -117.17M | -91.71M | -11.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Aggiornamento | Truist | Hold → Buy |
| 2021-07-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Downgrade | Truist | Buy → Hold |
| 2020-12-16 | Iniziato | UBS | Neutral |
| 2020-11-12 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-05 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-28 | Iniziato | Goldman | Buy |
| 2020-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-09-13 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-06-14 | Ripresa | Raymond James | Mkt Perform |
| 2018-11-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Downgrade | SunTrust | Buy → Hold |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Iniziato | SunTrust | Buy |
| 2018-02-15 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie
Adverum Biotechnologies (NASDAQ:ADVM) Stock Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
3 US Penny Stocks With Market Caps Below $400M - Yahoo Finance
The Sonic Fund Solicits Proxies from Shareholders of Adverum Biotechnologies -April 13, 2021 at 04:16 pm EDT - Marketscreener.com
Adverum Biotechnologies (NASDAQ:ADVM) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Gene Therapy Pioneer Adverum Takes Center Stage at Major Healthcare Conference - StockTitan
ADVM stock touches 52-week low at $4.01 amid market challenges - MSN
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $27.83 - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $27.83 Average PT from Analysts - Defense World
Barclays PLC Buys 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Comparing Adverum Biotechnologies (NASDAQ:ADVM) & Pluri (NASDAQ:PLUR) - Defense World
Adverum Biotechnologies stock hits 52-week low at $4.4 - Investing.com
Adverum Biotechnologies stock hits 52-week low at $4.4 By Investing.com - Investing.com South Africa
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Target Price at $27.83 - Defense World
Geode Capital Management LLC Sells 16,731 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Barclays PLC Purchases 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
State Street Corp Boosts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Increase in Short Interest - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Large Increase in Short Interest - MarketBeat
Adverum Biotechnologies stock hits 52-week low at $4.61 - Investing.com
Adverum Biotechnologies (NASDAQ:ADVM) Cut to Sell at StockNews.com - Defense World
StockNews.com Downgrades Adverum Biotechnologies (NASDAQ:ADVM) to Sell - MarketBeat
Where are the Opportunities in (ADVM) - Stock Traders Daily
Fmr LLC Lowers Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Sold by Fmr LLC - MarketBeat
Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 11.1% in November - MarketBeat
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Drops By 11.1% - Defense World
ADVM stock touches 52-week low at $5.61 amid market challenges - Investing.com
StockNews.com Upgrades Adverum Biotechnologies (NASDAQ:ADVM) to Hold - Defense World
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Awards Key Talent Inducement Grants, Strengthens Team with Strategic Equity Package - StockTitan
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Biotechnologies Grants 55,000 Share Stock Option Package to New Employee | ADVM Stock News - StockTitan
Thinking about buying stock in Adverum Biotechnologies, Roma Gre - GuruFocus.com
Adverum Biotechnologies (NASDAQ:ADVM) Receives Buy Rating from HC Wainwright - MarketBeat
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients (NASDAQ:ADVM) - Seeking Alpha
Adverum Biotechnologies Announces Positive 52-Week LUNA and - GlobeNewswire
Adverum Biotechnologies, Inc. Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 5.9% in October - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adverum Biotechnologies Inc Azioni (ADVM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Jul 17 '24 |
Buy |
7.75 |
135,546 |
1,049,926 |
2,101,546 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
9.11 |
80,718 |
735,736 |
2,182,264 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):